Mark Alvino Sells 2,000 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Mark Alvino sold 2,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $5.09, for a total transaction of $10,180.00. Following the sale, the director directly owned 84,065 shares of the company’s stock, valued at approximately $427,890.85. This represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mark Alvino also recently made the following trade(s):

• On Wednesday, January 21st, Mark Alvino sold 13,500 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.23, for a total value of $70,605.00.
• On Thursday, November 13th, Mark Alvino sold 15,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $4.74, for a total value of $71,100.00.

Abeona Therapeutics Trading Up 1.9%

Shares of NASDAQ ABEO opened at $5.27 on Wednesday. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54. The company has a market cap of $285.58 million, a price-to-earnings ratio of 4.28 and a beta of 1.18. The business has a fifty day simple moving average of $5.17 and a 200-day simple moving average of $5.58.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.17. Sell-side analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Abeona Therapeutics News Roundup

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Institutional buying: multiple funds disclosed new or larger stakes in ABEO (AIGH Capital Management, Aberdeen Group among others), signaling professional investor interest that can support the share price. MarketBeat Institutional Trading
• Positive Sentiment: Recent quarter topped expectations: Abeona reported -$0.10 EPS vs. Street -$0.27 on Nov. 12, which is a positive fundamental surprise for a clinical-stage biotech that can lift sentiment. Earnings Recap
• Positive Sentiment: Balance sheet and liquidity appear strong (high current and quick ratios, low debt-to-equity), reducing near-term financing risk for clinical programs — a positive for risk-sensitive investors. Financials
• Neutral Sentiment: Analyst landscape is mixed but tilted positive: several buy ratings and an average target materially above the current price (MarketBeat cites an average target near $20), though opinions vary. Analyst Notes
• Neutral Sentiment: Inclusion on retail/investor lists: Abeona appeared in a Yahoo Finance roundup of “Insider-Favored Growth Companies To Watch,” which can boost visibility but is not a fundamental catalyst by itself. Yahoo Article
• Neutral Sentiment: Short-interest notes show effectively zero reported short interest and a 0.0 days-to-cover figure in recent reports — likely a reporting artifact and not meaningful market pressure at present.
• Negative Sentiment: Insider selling: several directors sold shares on Feb. 2 (Leila Alland sold 18,065 shares; Eric Crombez sold 16,284 shares; Mark Alvino sold 2,000 shares). Large or clustered director sales can weigh on sentiment even if they may be liquidity-driven. Recent filings: SEC/InsiderTrades disclosures. InsiderTrades Article SEC Filing

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently made changes to their positions in ABEO. Boone Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter valued at $7,126,000. AWM Investment Company Inc. bought a new position in Abeona Therapeutics during the second quarter valued at about $2,670,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Abeona Therapeutics in the second quarter worth about $581,000. Simplify Asset Management Inc. boosted its stake in shares of Abeona Therapeutics by 36.7% during the 2nd quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock worth $3,173,000 after acquiring an additional 150,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $1,523,000. Institutional investors own 80.56% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ABEO shares. Wall Street Zen downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, October 13th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.